Clinical trials

Condition   Drug Name  
Study MEDI-545 in psoriasis: The NCT00472758 study
Design Randomized; Double-blind; Multicenter
Patients 40
Treatment Regimen MEDI-545 i.v.; Placebo
Conclusions The safety and tolerability of escalating single intravenous doses of MEDI-545 in patients with psoriasis will be determined in a phase I study initiated in April 2007
Reference(s) A phase 1, randomized, double-blind, placebo-controlled, dose-escalation, multicenter study to evaluate the safety and tolerability of single-dose for MEDI-545, (CP145) (NCT00472758) Web Site 2007